That is correct, and it is one of the proposed amendments we have suggested. Make it crystal clear that the implementation is only to be on a go-forward basis.
If you take a $100 million drug—and there are many, many of those in the Canadian market—and you delay a generic competitor for two years, who would sell it at 20% of the price, you're adding $80 million a year just for one drug. These costs are very significant and should not be ignored. As I said, if done properly, the CETA negotiations and the bill should ensure that they occur only in the future.